Abstract

Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration

Author(s): Lu Juan, Liu Qiang, Kupiec Thomas C, Vail Herbert, Lynch Leslie R, Fam David S, Vu Nicole T

Issue: Jan/Feb 2021 - Volume 25, Number 1

Page(s): 52-61

Download in electronic PDF format for $75
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 1
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 2
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 3
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 4
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 5
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 6
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 7
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 8
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 9
  • Physical Compatibility of Cefiderocol with Selected Intravenous Drugs During Simulated Y-site Administration Page 10

Note: Electronic version includes errata or revisions.

Abstract

The physical compatibility of cefiderocol for injection (prepared as a diluted 2% cefiderocol solution) with potential co-administration drug products is presented. The compatibility of cefiderocol with a selection of 91 intravenous drugs was tested at clinically relevant concentrations using the admixed volume ratio 1:1. Compatibility of the mixtures was determined by visual observations, turbidity, and particulate-matter measurements. The mixtures were examined immediately after mixing, and then at 1 hour and 4 hours thereafter at room temperature. When using 0.9% sodium chloride or 5% dextrose injection for diluents, solutions of dobutamine hydrochloride, esomeprazole sodium, methylprednisolone acetate, propofol, rocuronium bromide, amiodarone hydrochloride, famotidine, labetalol hydrochloride, mycophenolate mofetil, acyclovir sodium, amphotericin B, caspofungin acetate, doxycycline, posaconazole, diphenhydramine hydrochloride, and phenytoin sodium were found to cause visible cloudiness upon mixing with 2% cefiderocol in both diluents. Solutions of lorazepam, tobramycin sulfate, and vancomycin hydrochloride were determined incompatible by examining the mixtures with the aid of a Tyndall light. These 19 drugs were clearly incompatible with cefiderocol for injection by visual examination. In addition, solutions of iron sucrose and albumin were incompatible with 2% cefiderocol based on sub-visual tests for turbidity and/or particulate matter. Based on sub-visual data, the 0.9% sodium chloride admixture of aminophylline and 2% cefiderocol was incompatible, while inconclusive results were obtained for the 0.9% sodium chloride admixtures of 2% cefiderocol with amikacin sulfate. Similarly, the 5% dextrose admixtures of either ciprofloxacin or polymyxin B sulfate with 2% cefiderocol were incompatible, whereas data for phenylephrine hydrochloride morphine sulfate, or undiluted sodium bicarbonate were inconclusive. Overall, the 2% cefiderocol solution was physically compatible with 63 of 91 drugs challenged at 1:1 volume ratio in both 0.9% sodium chloride and 5% dextrose diluents for at least 4 hours at the concentrations tested in this study.

Related Keywords

Related Categories

Printer-Friendly Version

Related Articles from IJPC

Issue/Page
View/Buy
Title/Author
(Click for Abstract / Details / Purchase)
Jan/Feb 2021
Pg. 52-61
Mar/Apr 2025
Pg. 121
Author(s):
Jul/Aug 2002
Pg. 311-315
May/Jun 2008
Pg. 276-278
Nov/Dec 2007
Pg. 520-524
Jan/Feb 2001
Pg. 69-73
May/Jun 1999
Pg. 241-244
Jul/Aug 2008
Pg. 368-371
Mar/Apr 2008
Pg. 170-173
May/Jun 2006
Pg. 230-233
Jan/Feb 2009
Pg. 78-80
Nov/Dec 2022
Pg. 522-526
Jul/Aug 2016
Pg. 328-332
Mar/Apr 2008
Pg. 156-160
Sep/Oct 2007
Pg. 426-432
Jul/Aug 2001
Pg. 314-319
May/Jun 2002
Pg. 230-233
May/Jun 2016
Pg. 236-238
Jan/Feb 2020
Pg. 44-50
Author(s): Allen Loyd V Jr
Jan/Feb 2007
Pg. 82-85